Name | (4S)-6-Chloro-7-(4-{[2-(4-chloro-2-methoxyphenyl)ethyl]carbamoyl}phenoxy)-4-chromanecarboxylic acid |
---|---|
Synonyms |
2H-1-Benzopyran-4-carboxylic acid, 6-chloro-7-[4-[[[2-(4-chloro-2-methoxyphenyl)ethyl]amino]carbonyl]phenoxy]-3,4-dihydro-, (4S)-
(4S)-6-Chloro-7-(4-{[2-(4-chloro-2-methoxyphenyl)ethyl]carbamoyl}phenoxy)-4-chromanecarboxylic acid |
Description | ARRY-502 is an orally bioavailable, potent and selective antagonist of the prostaglandin D2 receptor (CRTh2) for treatment of mild to moderate Th2-driven asthma. Asthma Phase 2 Discontinued |
---|---|
References | References View Related Products by Target Prostaglandin Receptor Asthma |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 686.1±55.0 °C at 760 mmHg |
Molecular Formula | C26H23Cl2NO6 |
Molecular Weight | 516.370 |
Flash Point | 368.8±31.5 °C |
Exact Mass | 515.090271 |
LogP | 4.95 |
Vapour Pressure | 0.0±2.2 mmHg at 25°C |
Index of Refraction | 1.619 |